On and effective June 15, 2022, VistaGen Therapeutics, Inc. (the Company) terminated the employment of H. Ralph Snodgrass, Ph.D., who served as the Company's President and Chief Scientific Officer.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
4.17 USD | -2.11% | -7.91% | -18.48% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-18.48% | 12Cr | |
+10.39% | 12TCr | |
+12.69% | 11TCr | |
-4.30% | 2.47TCr | |
-1.89% | 2.2TCr | |
-5.52% | 1.93TCr | |
-12.04% | 1.76TCr | |
-39.36% | 1.73TCr | |
+6.02% | 1.4TCr | |
+32.57% | 1.21TCr |
- Stock Market
- Equities
- VTGN Stock
- News Vistagen Therapeutics, Inc.
- VistaGen Therapeutics, Inc. Terminates Employment of H. Ralph Snodgrass as President and Chief Scientific Officer